SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

soquelitinib

CRVS·Corvus Pharmaceuticals, Inc.
NEUTRAL
Drug Impact Rating7/10
Trial phase
Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
Time to market
If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
Why 7/10
The next hard, dated catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months from today). Soquelitinib is Corvus's only clinical-stage asset and drives essentially the entire investment thesis, making this a high-impact binary event. The impact score of 7 reflects that this is an interim futility analysis (not a final efficacy readout or PDUFA) on a single-asset company, with the catalyst within ~6 months.
Actionable Insight NEUTRAL

The next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.

Price Chart

Loading chart...

Executive Summary

Soquelitinib (CPI-818) is Corvus Pharmaceuticals' lead and only clinical-stage asset, an oral, first-in-class selective ITK inhibitor being developed for T-cell lymphoma and immune-inflammatory diseases. The drug has shown promising Phase 1/1b data in relapsed/refractory peripheral T-cell lymphoma (PTCL) with a 37.5% ORR and 28.1-month median OS, published in the journal Blood. A registrational Phase 3 PTCL trial (NCT06561048, n=150) is enrolling with an interim futility analysis expected in Q1 2027. The drug is also being tested in a Phase 2 atopic dermatitis trial (SIERRA1, topline Q3 2027), a Phase 2 ALPS trial (ASH presentation Dec 14, 2026), and a Phase 1b hidradenitis suppurativa trial. Corvus has $202.9 million in cash (Q3 2026), funding operations into Q2 2028. Analyst consensus is Strong Buy with a mean price target of $31.50, but the stock trades at $9.73, reflecting the binary risk of the upcoming Phase 3 interim analysis and the long wait for data readouts.

How It Works

Soquelitinib is an oral pill that selectively blocks an enzyme called ITK (interleukin-2-inducible T-cell kinase), which is found mainly in T-cells, a type of immune cell. By inhibiting ITK, the drug shifts the immune system away from inflammatory responses (Th2 and Th17 pathways) and toward a more balanced, anti-tumor immune state (Th1 skewing). This makes it potentially useful for both T-cell cancers (where it helps the immune system attack cancer cells) and inflammatory diseases like eczema (atopic dermatitis), where it dampens the overactive immune response.

Trial Status

The registrational Phase 3 PTCL trial (NCT06561048) began enrollment in October 2024, targeting 150 patients across 34 sites, with an interim futility analysis expected in Q1 2027 and primary completion estimated in November 2027. The Phase 2 SIERRA1 atopic dermatitis trial (NCT07441395) began enrollment in early 2026 with 200 target patients, topline data expected Q3 2027. A Phase 2 ALPS trial (NIAID-led) has enrolled 3 patients with one-year data to be presented at ASH December 2026. A Phase 1b hidradenitis suppurativa trial is enrolling with initial data expected 1H 2027. Partner Angel Pharmaceuticals completed cohort 1 enrollment in a Phase 1b/2 atopic dermatitis trial in China, with topline data anticipated March 2027.

The Two-Sided Case

▲ Bull Case5
Soquelitinib has a novel, differentiated mechanism as a first-in-class oral selective ITK inhibitor with over 100-fold selectivity over related kinases, offering a potential new treatment approach for T-cell lymphomas and immune-inflammatory diseases.
Phase 1/1b PTCL data published in Blood showed a 37.5% overall response rate and a median overall survival of 28.1 months in the 200 mg BID cohort, comparing favorably to historical results with current therapies. The FDA granted both Orphan Drug and Fast Track designations.
The company has a strong cash runway: $202.9 million as of September 30, 2026, funding operations into Q2 2028, following a $189.4 million financing in January 2026. This eliminates near-term dilution risk.
Institutional ownership is substantial with BlackRock ($106.7M), State Street ($66.8M), and T. Rowe Price ($56.6M) as top holders as of Q2 2026. Multiple funds added or doubled positions in Q2 2026.
Analyst consensus is Strong Buy (12 analysts: 5 strong buy, 7 buy, 1 hold) with a mean price target of $31.50, representing significant upside from the current $9.73 price. The drug is being developed across multiple indications (PTCL, atopic dermatitis, ALPS, hidradenitis suppurativa, asthma), providing pipeline optionality.
▼ Bear Case5
Soquelitinib is still in clinical development with no approved products or revenue; the company reported a Q3 2026 net loss of $20.3 million. The Phase 3 PTCL futility analysis in Q1 2027 is a binary risk: if the interim analysis fails, the entire oncology program could be jeopardized.
The Phase 1/1b PTCL data (37.5% ORR, n=~32) came from a small, uncontrolled trial. Larger randomized Phase 3 data may not replicate those results against active comparators (belinostat or pralatrexate).
The atopic dermatitis market is crowded with approved JAK inhibitors and biologics (Dupixent, Rinvoq, Cibinqo). Soquelitinib's Phase 2 data in Q3 2027 will need to show a clear differentiation to justify further investment.
The stock has fallen from a 52-week high of $26.95 to $9.73 (Nov 5 close), reflecting the long wait for catalysts and potential concerns about execution risk. Several institutional holders trimmed or exited positions in Q2 2026, including Morgan Stanley (trim -46%) and Polar Capital (full exit).
Analyst coverage is stale (last action April 2026), and the mean price target of $31.50 may not reflect recent clinical or competitive developments.

Upcoming Catalysts

  • ASH 2026 Annual Meeting (Dec 14, 2026): Poster presentation of initial Phase 2 ALPS data (n=3, one-year follow-up)
  • Q1 2027: Phase 3 PTCL interim futility analysis - a binary readout that could stop or continue the registrational trial
  • March 2027: Angel Pharma (China partner) Phase 1b/2 atopic dermatitis topline data
  • 1H 2027: Phase 1b hidradenitis suppurativa initial data
  • Q3 2027: SIERRA1 Phase 2 atopic dermatitis topline data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Corvus Pharmaceuticals, Inc. Press Release CRVS ·Originating report

Sources · 13

Hover a chip for the title
1 investor.corvuspharma.com2 investor.corvuspharma.com3 clinicaltrials.gov4 investor.corvuspharma.com5 investor.corvuspharma.com6 cancernetwork.com7 biospace.com8 panabee.com9 marketbeat.com10 seekingalpha.com11 sec.gov12 en.wikipedia.org13 onclive.com